News
FDA Approves First Twice-a-Year HIV Prevention Shot
FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be taken twice a year. On Wednesday, the U.S. Food and Drug Administration (FDA) approved lenacapavir, a long-acting injection that was shown to be nearly 100% effective in clinical trials.
The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...
Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback